Understanding unfolding and refolding of the antibody fragment (Fab). I. In-vitro study

December 15, 2020

Gani, K., Bhambure, R., Deulgaonkar, P., et al.

Biochemical Engineering Journal 2020, vol: 164 doi: 10.1016/j.bej.2020.107764

Abstract

In-vitro protein refolding is a major rate-limiting step in the large scale production of antibody fragments expressed using a microbial source like E. coli. This investigation is focused on understanding the in-vitro unfolding and refolding of the multi-domain protein involving inter-domain disulfide linkage, like antibody fragment (Fab). Solubilization behavior of the inclusion bodies and unfolding events of Fab fragment (Biosimilar rHu Ranibizumab) were studied using nano-differential scanning fluorimetry (nano-DSF). Fab unfolding behavior was studied by fitting experimental data with the two-state and three-state thermodynamic model. Based on the Fab unfolding understanding, a two-stage design of experiment (DoE) strategy was used for the optimization of the in-vitro refolding condition of a Fab fragment. Refolding yield of 56.03 ± 1.15 % was achieved using the optimized oxidative refolding conditions maintained by appropriate dilution factor and redox reagent ratio. Refolding kinetics of the rHu Ranibizumab was analyzed using a three-parameter kinetic model showing rate constant k1:7.05e-6 l/mg.min, k2:0.57 l/mg.min, and k3:310.19 l/mg.min. Based on observed refolding kinetics, it was concluded that the Fab refolding follows a three-state mechanism with the refolding intermediate/(s) formation from light and heavy chain of the Fab fragment as an overall rate-limiting step. The method described here is a useful tool to identify high-yield scalable refolding conditions for multi-domain proteins involving inter-domain disulfide bonds.

View Publication

Topics: Prometheus, nanoDSF, Biologics, Publications

Previous Video
Measuring stability to more effectively select therapeutic antibody candidates
Measuring stability to more effectively select therapeutic antibody candidates

This therapeutic antibody drug development webinar discusses the idea of limiting the substantial investmen...

Up next
Evaluation of slow equilibration kinetics in antibody chemical denaturation experiments
Evaluation of slow equilibration kinetics in antibody chemical denaturation experiments

Looking for the optimal formulation for your biologics candidates?

NanoTemper tools can help

Find out how